Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palifosfamide - Alaunos Therapeutics

Drug Profile

Palifosfamide - Alaunos Therapeutics

Alternative Names: IPM (ZIO-201); IPM-tris; Isophosphamide mustard-tris; Isophosphoramide mustard; Palifosfamide-tris; ZIO-201; ZIO-201-T; Zymafos

Latest Information Update: 31 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dekk-Tec
  • Developer Alaunos Therapeutics; ZIOPHARM Oncology
  • Class Antineoplastics; Cyclophosphamides; Oxazines; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Haematological malignancies; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Testicular cancer

Most Recent Events

  • 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top